Health Awareness Topics - February 2012
See the updated Mobile Resources
page for information concerning the availability of full-text guidelines and/or companion documents available in downloadable versions for hand-held devices.
The Guidelines International Network (G-I-N) Conference 2012
, will be held August 22-25, 2012
in Berlin, Germany. Registration
is now open.
U.S. Food and Drug Administration (FDA) Advisories
- February 9, 2012: Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs : FDA notified healthcare professionals and patients that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medicines when they are used together.
- February 8, 2012: Proton Pump Inhibitors (PPIs) : FDA notified the public that the use of stomach acid drugs known as proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile–associated diarrhea (CDAD). A diagnosis of CDAD should be considered for patients taking PPIs who develop diarrhea that does not improve. The FDA is working with manufacturers to include information about the increased risk of CDAD with use of PPIs in the drug labels.
NGC's Sister Resources